← All trials
NCT05213767
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jul 31, 2023
- First posted
- Jan 28, 2022
- Last posted
- Jan 28, 2022
- Enrollment
- 190
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.